Skip to main content
OpenTrials
Completed

NCT Number: NCT03335722

Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter

This study aims to test whether the application of transcranial direct current stimulation (tDCS) concurrent with fluency training results in improvements in speech fluency in adults with developmental stuttering, measured up to three months after the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Department of Experimental Psychology, University of Oxford

Oxford, OX2 6BW, United Kingdom

About this study

Developmental stuttering affects 5% of children and persists to adulthood in about 1%. Changing the way speech is produced in adults who stutter is a particular challenge for speech and language therapy and there is a need for novel interventions. One such intervention involves the application of transcranial direct current stimulation (tDCS) alongside therapies aimed at improving speech fluency. tDCS influences brain activity by modulating neuronal plasticity through the application of weak electrical currents across the brain. Pairing tDCS with speech therapy has potential for producing larger or longer lasting effects and reducing time spent in therapy.

The study will evaluate the potential of tDCS combined with speech fluency training to improve outcomes in people who stutter (PWS). PWS will have this training while receiving tDCS for five days (1 milliampere [mA] for 20 mins per day) in a double-blind randomized controlled trial. Outcomes will be measured in terms of changes to stuttering severity.

An additional research questions is how changes in interactions between sensory and motor brain regions relate to changes in speech fluency in PWS. MRI will be used to measure brain structure and function and the vocal tract during speech production. Transcranial magnetic stimulation (TMS) will assess motor excitability before and after the training.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is willing and able to give informed consent for participation in the study.
  • Diagnosed with developmental stuttering of mild-moderate or greater severity
  • Native speaker of English
  • Normal or corrected-to-normal vision
  • Normal hearing

Exclusion criteria

  • Speech, language or communication disorder other than developmental stuttering.
  • Contraindication to brain stimulation (tDCS or TMS)
  • Contraindication to MRI
  • History of drug abuse
  • History of a neurological or psychiatric illness
  • Any previous neurosurgical procedures
  • Taking prescription or over-the-counter medication that may affect brain function (for example, anti-depressants)
  • Family history of epilepsy (first degree relative)
  • Severe claustrophobia (as they may be unable to tolerate scanner)

Treatment and study plan

Metronome-timed speech

Behavioral

Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.

active tDCS

Device

1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.

Sham tDCS

Device

Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.

Primary outcomes

  1. Change in Stuttering Severity Instrument (SSI-4) Score

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    The Stuttering Severity Instrument (SSI-4) is a standardised measure of stuttering severity comprised of 3 sub-scores (frequency, duration and physical concomitants) which are summed to give a total score. We will use change from baseline in total score (i.e. baseline subtracted) on the Stuttering Severity Instrument version 4 measured post intervention. The maximum total score of the SSI-4 is 56, which corresponds to the highest stuttering severity. Therefore, larger negative change scores represent better outcomes (larger reductions in stuttering severity).

Secondary outcomes

  1. Change in percentage of disfluent syllables produced during conversation

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute conversation sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency).

  2. Change in percentage of disfluent syllables produced during reading

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change from baseline (i.e. baseline subtracted) in percentage of disfluent syllables produced during a two-minute reading sample. Larger negative change scores represent better outcomes (larger reductions in frequency of disfluency).

  3. Change in Overall Assessment of the Speaker's Experience of Stuttering (OASES) score

    Time frame: 6 weeks and 12 weeks after the end of the 5-day intervention

    The Overall Assessment of the Speaker's Experience of Stuttering (OASES) is a standardised self-assessment to measure the effect of stuttering on a person's life, comprising of 4 sub-scores (general information about speech, your reactions to stuttering, communication in daily situations, quality of life). The total score (out of a possible 500) is divided by the number of items (out of a possible 100. Note that some items may not apply to all participants). This gives a total impact score between 1 and 5, with 5 representing the highest negative impact on person's life.

    We will use change from baseline in total score (i.e. baseline subtracted) on the OASES total impact score, measured post intervention, as an outcome. Larger negative change scores represent better outcomes (larger reductions in negative impact of stuttering ).

Other outcomes

  1. Change in Premonitory Awareness in Stuttering Scale

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change in total score on measure of anticipation of stuttering

  2. Change in Beck Anxiety Inventory

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change in total score on the Beck Anxiety Inventory

  3. Change in Subjective rating of stuttering severity

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change in self-rating on 9 point scale

  4. Change in Subjective rating of speech naturalness

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change in self-rating on 9 point scale

  5. Change in Objective rating of stuttering severity

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change in Researcher rating on 9 point scale

  6. Change in Objective rating of speech naturalness

    Time frame: 1 week, 6 weeks and 12 weeks after the end of the 5-day intervention

    Change in Researcher rating on 9 point scale

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Registry information

Acronym: INSTEP

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Nov 8, 2017
Registry last updated
May 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.